홈MCP워크벤치Skills
홈워크벤치알림마이페이지
Huagongshe 오픈 프로젝트：[email protected]AI 접속: llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.7.8
돌아가기
Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
HCID 2710생성일: 2026년 10월 27일

Chlorcyclizine

Perazyl · Histantin · Trihistan · Alergicide · Di-paralen · Histantine · piparalene · Chlorcycline

https://huagongshe.com/ko/chemical/2710

Chlorcyclizine 분자 구조식

식별자 및 물리적 특성

CAS No.82-93-9
분자식C18H21ClN2
평균 분자량300.8 g/mol
단동위원소 질량300.13932635 g/mol
SMILESCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
InChIKeyWFNAKBGANONZEQ-UHFFFAOYSA-N
PubChem CID2710
ChEMBLCHEMBL22150
ChEBICHEBI:94402
EC No.201-446-0
DTXSIDDTXSID9048011

화학 및 물리적 성질

XLogP4.5
극성 표면적6.5
수소 결합 공여자 수0
수소 결합 수용자 수2
회전 가능 결합 수3
무거운 원자 수21
형식 전하0
복잡도300
LogP(분배 계수)LogP = 3.454.15
Color/FormOil
용해도1 G SOL IN ABOUT 2 ML H2O, 11 ML ALC1 G SOL IN ABOUT 4 ML CHLOROFORMPRACTICALLY INSOL IN ETHER, BENZENE /CHLORCYCLIZINE HYDROCHLORIDE/FREELY SOL IN WATERSOL IN ALC /CHLORCYCLIZINE DIHYDROCHLORIDE/
인화점No Data
Human DrugsPharmaceuticals
끓는 점137-145 °C @ 0.1-0.15 MM HGbp0.1-0.15 137-145°
녹는점MP: 226-227 °C /CHLORCYCLIZINE HYDROCHLORIDE/25°C
Dissociation ConstantsPKA(1)= 7.81 & PKA(2)= 2.43
Collision Cross Section172.21 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]
Other Experimental PropertiesODORLESS OR ALMOST ODORLESSITS SOLN ARE ACID TO LITMUSPH (1 IN 100 SOLN) BETWEEN 4.8 & 5.5 /CHLORCYCLIZINE HYDROCHLORIDE/AQ SOLN IS ACID TO LITMUS /CHLORCYCLIZINE DIHYDROCHLORIDE/WHITE, CRYSTALLINE POWDER /CHLORCYCLIZINE HYDROCHLORIDE/PRISMS FROM ALCOHOL PLUS ETHER /CHLORCYCLIZINE DIHYDROCHLORIDE/Solutions acid to litmus, pH (1 to 100 solution) 4.8-5.5 /Chlorcyclizine hydrochloride/
밀도1.0732 (rough estimate)
굴절률1.5749 (estimate)
저장 조건Store at -20°C
pKa(산도 계수)pKa 2.43(H2O t = 25 c = 0.002 to 0.01)(Approximate)7.81(H2O t = 25 c = 0.002 to 0.01) (Uncertain)
용해도300.8mg/L(37.5℃)

안전 및 규제

GHS 분류WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P273, P301+P317, P330, P391, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
FDA 요건Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended21 U.S.C. 321-392).
Hazard Classes and CategoriesAcute Tox. 4 (100%)
처리 방법SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
상호 작용SEVERAL REVIEWS BRIEFLY MENTIONED THAT ANTIHISTAMINES INTERFERE WITH ANTICOAGULANT THERAPYHOWEVER, NO DOCUMENTATION WAS PRESENTED, NO CASE REPORTS OF ANTICOAGULATION PROBLEMS CAUSED BY ANTIHISTAMINES HAVE APPEARED. /ANTIHISTAMINES/TERATOGENICITY OF CHLORCYCLIZINE IN MICE...IS DIMINISHED BY PRE-TREATMENT EITHER WITH SKF 525A /PROADIFEN/ OR WITH PHENOBARBITONE, & MORE THAN ONE BIOTRANSFORMATION MUST BE INVOLVED.Plocamadine A (1 ug/ml) produced a slow onset, sustained contraction of the guinea-pig isolated ileum. This was insensitive to atropine (1 umol/l) and tetrodotoxin (1 umol/L), but was significantly reduced by H1-histamine receptor antagonists including mepyramine (10 nmol/l), chlorcyclizine (10 nmol/l) and diphenhydramine (0.1 umol/l).A method to determine whether chlorcyclizine hydrochloride (I) antihistamine activity could be demonstrated when I was applied topically in combo with 0.5% hydrocortisone acetate (MantadilII) cream was described. Hydrocortisone 5%, II, and placebo cream were studied in 30 subjects. The data indicated that a wheal and flare reaction induced in the subjects was decr by the I component of the combo. /Chlorcyclizine hydrochloride/
Human Toxicity Excerpts...NO EVIDENCE OF HARM TO HUMAN FETUS HAS BEEN REPORTED DESPITE WIDE USE OVER...PAST 15 YEARS.
ADULTS HAVE SURVIVED SINGLE DOSES OF 2.5-5.0 G. CHILDREN MAY BE DISPROPORTIONATELY MORE SUSCEPTIBLE
30-60 MG/KG HAS PRODUCED SERIOUS POISONINGS & DEATH IN TODDLERS, & IN 1 FATAL CASE DOSE WAS ABOUT 10 MG/KG. /ANTIHISTAMINICS/
.../AFTER/ EXTENSIVE EPIDEMIOLOGICAL INVESTIGATIONS IN SWEDEN, CANADA & US... THERE WAS DISAGREEMENT AS TO WHETHER CHLORCYCLIZINE WAS A TERATOGEN IN HUMANS
EPIDEMIOLOGIC INVESTIGATION OF CHLORCYCLIZINE COULD NOT PROVE EXISTENCE OF HARMFUL EFFECT IN HUMANS.
In acute poisoning with H1 antagonists, their central excitatory effects constitute the greatest danger. The syndrome includes hallucinations, excitement, ataxia, incoordination, athetosis, and convulsions. Fixed, dilated pupils with a flushed face, together with sinus tachycardia, urinary retention, dry mouth, and fever, lend the syndrome a remarkable similarity to that of atropine poisoning. Terminally, there is deepening coma with cardiorespiratory collapse and death, usually within 2 to 18 hours. /H1 Antagonists/
Drug Induced Liver InjuryDrug-Induced Liver Injury Severity and Toxicity (DILIst)chlorcyclizineDILI PositiveOralDOI:10.1016/j.drudis.2019.09.022
Non-Human Toxicity ExcerptsWHEN CHLORCYCLIZINE WAS ADMIN TO RATS @ ORAL DOSAGE OF 50 MG/KG DAILY FROM 10TH-15TH DAY OF PREGNANCY, HIGH INCIDENCE OF CLEFT PALATES WAS OBSERVED. ... /WHEN/ GIVEN SAME DAILY DOSAGE...FROM 1ST-15TH DAY OF PREGNANCY, INCIDENCE OF MALFORMATIONS...MARKEDLY REDUCED. ...STUDIES SHOWED THAT.../NORCHLORCYCLIZINE WAS RESPONSIBLE/.CHLORCYCLIZINE IS A MORE POTENT TERATOGEN THAN CYCLIZINE BUT DID NOT PRODUCE AS MANY FETAL DEATHS, ALTHOUGH SIMILAR SPECTRUM OF MALFORMATIONS WAS SEEN.TREATMENT /OF PREGNANT SPRAGUE-DAWLEY RATS/ ON VARIOUS DAYS FROM 10-15 WITH CYCLIZINE RESULTED IN 30% RESORPTIONS & APPROX 40% MALFORMED FETUSES. MALFORMATIONS INCL CLEFT PALATE, BRACHYGNATHIA & MICROSTOMIA. ...ALSO FAILURE TO OSSIFY IN...BONES. CATARACTS...DETECTED...& WERE COMMON & CONSISTENT FINDING. /CYCLIZINE/NORCHLORCYCLIZINE IS ABLE TO INDUCE SAME ARRAY OF MALFORMATIONS AS CHLORCYCLIZINE...& IS PROBABLY THE TERATOGENIC AGENT. HOWEVER, CO-ADMIN OF ACTIVE CMPD WITH CHLORCYCLIZINE REDUCED INCIDENCE OF CLEFT PALATE DUE TO UNCHANGED CHLORCYCLIZINE BUT NOT OTHER MALFORMATIONS DUE TO NORCHLORCYCLIZINE.For more Non-Human Toxicity Excerpts (Complete) data for CHLORCYCLIZINE (14 total), please visit the HSDB record page.
유해 물질 데이터82-93-9(Hazardous Substances Data)